IFNAR1 and cancer: Increasing evidences have shown that dysregulation of PTPN22 offers the potential to improve cancer immunotherapy not only by regulating IFNAR and TCR signaling pathway (29), but also includes the activation of 3 inflammasomes through the regulation of autophagy and the pyrin domain of the NLR family (30).